VEGFA and cancer: Although anti–vascular endothelial growth factor (VEGF) agents like bevacizumab (AvastinTM, a humanized monoclonal antibody against VEGF; Genentech (South San Francisco, CA, USA)) are perhaps most discussed [1], many other compounds have been identified and are currently in various phases of clinical cancer trials [2,3].